SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Biocept Inc. – ‘10-Q’ for 3/31/22

On:  Monday, 5/23/22, at 2:42pm ET   ·   For:  3/31/22   ·   Accession #:  1564590-22-20962   ·   File #:  1-36284

Previous ‘10-Q’:  ‘10-Q/A’ on 2/15/22 for 9/30/21   ·   Next:  ‘10-Q’ on 11/10/22 for 6/30/22   ·   Latest:  ‘10-Q’ on 8/14/23 for 6/30/23   ·   25 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 5/23/22  Biocept Inc.                      10-Q        3/31/22   69:8.2M                                   ActiveDisclosure/FA

Quarterly Report   —   Form 10-Q

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML    940K 
 2: EX-10.1     Material Contract                                   HTML    262K 
 3: EX-31.1     Certification -- §302 - SOA'02                      HTML     28K 
 4: EX-31.2     Certification -- §302 - SOA'02                      HTML     28K 
 5: EX-32.1     Certification -- §906 - SOA'02                      HTML     22K 
 6: EX-32.2     Certification -- §906 - SOA'02                      HTML     23K 
12: R1          Document and Entity Information                     HTML     74K 
13: R2          Condensed Balance Sheets                            HTML    114K 
14: R3          Condensed Balance Sheets (Parenthetical)            HTML     39K 
15: R4          Condensed Statements of Operations and              HTML     96K 
                Comprehensive Loss (Unaudited)                                   
16: R5          Condensed Statements of Shareholders' Equity        HTML     61K 
17: R6          Condensed Statements of Cash Flows (Unaudited)      HTML     90K 
18: R7          Condensed Statements of Cash Flows (Unaudited)      HTML     26K 
                (Parenthetical)                                                  
19: R8          The Company, Business Activities and Basis of       HTML    121K 
                Presentation                                                     
20: R9          Liquidity                                           HTML     27K 
21: R10         Sales of Equity Securities                          HTML     29K 
22: R11         Fair Value Measurement                              HTML     35K 
23: R12         Balance Sheet Details                               HTML    104K 
24: R13         Leases                                              HTML    177K 
25: R14         Stock-Based Compensation                            HTML     95K 
26: R15         Common Stock Warrants Outstanding                   HTML     66K 
27: R16         Net Loss per Common Share                           HTML     46K 
28: R17         Commitments and Contingencies                       HTML     25K 
29: R18         Related Party Transactions                          HTML     25K 
30: R19         Subsequent Events                                   HTML     23K 
31: R20         The Company, Business Activities and Basis of       HTML    127K 
                Presentation (Policies)                                          
32: R21         The Company, Business Activities and Basis of       HTML     94K 
                Presentation (Tables)                                            
33: R22         Fair Value Measurement (Tables)                     HTML     29K 
34: R23         Balance Sheet Details (Tables)                      HTML    103K 
35: R24         Leases (Tables)                                     HTML    177K 
36: R25         Stock-Based Compensation (Tables)                   HTML     96K 
37: R26         Common Stock Warrants Outstanding (Tables)          HTML     63K 
38: R27         Net Loss per Common Share (Tables)                  HTML     45K 
39: R28         The Company, Business Activities and Basis of       HTML     46K 
                Presentation - Additional Information (Detail)                   
40: R29         The Company, Business Activities and Basis of       HTML     39K 
                Presentation - Composition of Net Revenues                       
                Recognized Disaggregated by Source (Detail)                      
41: R30         The Company, Business Activities and Basis of       HTML     34K 
                Presentation - Composition of Net Revenues                       
                Recognized Disaggregated by Nature (Detail)                      
42: R31         The Company, Business Activities and Basis of       HTML     39K 
                Presentation - Summary of Third-Party Payers That                
                Represent More Than 10% of Total Net Revenues and                
                Total Net Accounts Receivable and Their Related                  
                Percentage (Detail)                                              
43: R32         Liquidity - Additional Information (Detail)         HTML     53K 
44: R33         Sales of Equity Securities - Additional             HTML     66K 
                Information (Detail)                                             
45: R34         Fair Value Measurement - Additional Information     HTML     53K 
                (Detail)                                                         
46: R35         Fair Value Measurement - Assumptions Used for       HTML     38K 
                Determining Fair Values of Common Stock Warrants                 
                (Detail)                                                         
47: R36         Balance Sheet Details - Schedule of Fixed Assets    HTML     68K 
                and Accrued Liabilities (Detail)                                 
48: R37         Leases - Additional Information (Detail)            HTML    122K 
49: R38         Leases - Schedule of Right-Of-Use Lease Assets      HTML     26K 
                (Detail)                                                         
50: R39         Leases - Schedule of Current Portion of Operating   HTML     27K 
                and Finance Lease Liabilities (Detail)                           
51: R40         Leases - Schedule of Long-Term Portion of           HTML     27K 
                Operating and Finance Lease Liabilities (Detail)                 
52: R41         Leases - Schedule of Lease Expense (Detail)         HTML     30K 
53: R42         Leases - Schedule of Remaining Future Minimum       HTML     71K 
                Lease Payments for Finance and Operating Leases                  
                (Detail)                                                         
54: R43         Leases - Supplemental Cash Flow Information         HTML     28K 
                Related to Operating and Finance Leases (Detail)                 
55: R44         Stock-Based Compensation - Additional Information   HTML     73K 
                (Detail)                                                         
56: R45         Stock-Based Compensation - Summary of Stock Option  HTML     46K 
                Activity (Detail)                                                
57: R46         Stock-Based Compensation - Assumptions Used for     HTML     40K 
                Determining Fair Value of Stock Options Under                    
                Black-Scholes Pricing Model (Detail)                             
58: R47         Stock-Based Compensation - Effects of Stock-Based   HTML     34K 
                Compensation Related to Equity Awards to Employees               
                and Nonemployees on Condensed Statement of                       
                Operations and Comprehensive Loss (Detail)                       
59: R48         Common Stock Warrants Outstanding - Summary of      HTML     28K 
                Equity-Classified Common Stock Warrant Activity                  
                (Detail)                                                         
60: R49         Common Stock Warrants Outstanding - Additional      HTML     40K 
                Information (Detail)                                             
61: R50         Net Loss per Common Share - Additional Information  HTML     27K 
                (Detail)                                                         
62: R51         Net Loss per Common Share - Schedule of             HTML     34K 
                Anti-Dilutive Securities Excluded from                           
                Computations of Diluted Weighted-Average Shares                  
                (Detail)                                                         
63: R52         Commitments and Contingencies - Additional          HTML     29K 
                Information (Detail)                                             
64: R53         Related Party Transactions - Additional             HTML     29K 
                Information (Detail)                                             
67: XML         IDEA XML File -- Filing Summary                      XML    123K 
65: XML         XBRL Instance -- bioc-10q_20220331_htm               XML   1.68M 
66: EXCEL       IDEA Workbook of Financial Reports                  XLSX     78K 
 8: EX-101.CAL  XBRL Calculations -- bioc-20220331_cal               XML    162K 
 9: EX-101.DEF  XBRL Definitions -- bioc-20220331_def                XML    429K 
10: EX-101.LAB  XBRL Labels -- bioc-20220331_lab                     XML   1.17M 
11: EX-101.PRE  XBRL Presentations -- bioc-20220331_pre              XML    817K 
 7: EX-101.SCH  XBRL Schema -- bioc-20220331                         XSD    188K 
68: JSON        XBRL Instance as JSON Data -- MetaLinks              342±   517K 
69: ZIP         XBRL Zipped Folder -- 0001564590-22-020962-xbrl      Zip    276K 




        
Filing Submission 0001564590-22-020962 – SGML Text

Original SGML Text submitted by:  ActiveDisclosure/FA  (as Filing Agent) 

To view the SGML, please refresh
Refresh emoji
this page.


Top

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Tue., May 14, 11:00:17.5pm ET